
Stephenson Global Scholar Grants Program Awards $5.3 Million to Drive Breakthroughs in Pancreatic Cancer Research
The grants support a new generation of research that is collaborative, cross-institutional, and deeply innovative. The 2025 recipients are tackling some of the most urgent and complex challenges in pancreatic cancer—from using AI to flag high-risk patients for screening, to developing dual-targeting CAR T cells that attack both tumors and their fibrotic defenses, to uncovering how diabetes-linked DNA damage may trigger cancer. Their work spans early detection, immunotherapy, metabolic vulnerabilities, and precision medicine—and reflects the kind of interdisciplinary, translational science that is urgently needed to improve outcomes for patients.
2025 Stephenson Scholar Grant Recipients
Dr. Renier Brentjens and Dr. Leonid Cherkassky (Roswell Park)
Engineering Circuit-controlled T Cell Differentiation and Restructuring the Pancreatic Cancer Stroma to Optimize PDAC-targeted CAR T Cell Therapy for Clinical Translation
Creating next-generation CAR T cells that target both pancreatic tumors and their fibrotic stroma, using synthetic promoters to fine-tune T cell behavior, offering a promising new direction for pancreatic cancer immunotherapy.
Dr. Robert Grant (Princess Margaret/UHN)
Applying Artificial Intelligence to Electronic Health Records to Guide Pancreatic Cancer Screening
Utilizing large language models to analyze EHR data and flag high-risk individuals for screening—embedding AI directly into hospital systems to enable scalable early detection.
Dr. Costas Lyssiotis (University of Michigan)
Lysosomal Lipid Homeostasis is a Clinically Exploitable Vulnerability in KRAS-Inhibited Pancreatic Cancer
Targeting a unique metabolic vulnerability in KRAS-mutant tumors using clinically relevant drugs and synthetic lethality, with durable cures shown in preclinical models.
Dr. Sarah Shuck (City of Hope)
From Blood Sugar to Tumor Growth: How Diabetes Fuels Pancreatic Cancer Onset
Investigating how the sugar byproduct methylglyoxal leads to DNA mutations associated with pancreatic cancer and developing a novel blood-based screening tool.
Dr. Matthew Vander Heiden (MIT)
Assessment of Pancreas Organ Health for Pancreatic Cancer Early Detection
Developing a multimodal platform that combines stool, blood, and CT imaging to detect pancreatic cancer before symptoms appear and leveraging changes in organ function as early warning signs.
Dr. Forest White & Dr. Tyler Jacks (MIT)
Identification of Treatment-Associated Tumor Antigens for Targeted Immunotherapy in Pancreatic Cancer
Using mass spectrometry to identify new peptide antigens that emerge after KRAS inhibition, enabling novel vaccine and BiTE strategies that link targeted therapy with immunotherapy.
'These scientists' pioneering approaches represent the future of pancreatic cancer research,' said A. Emmet Stephenson Jr., co-founder of SGPCRI. 'Their work exemplifies the kind of innovative, collaborative thinking that the Stephenson initiative was created to support.'
'Pancreatic cancer took my mother far too soon, but my father and I know that groundbreaking science can change the future for so many other families who have faced this disease,' said Tessa Stephenson Brand. 'These grants are about hope, urgency, and the belief that progress is possible.'
The Stephensons made their investment in honor of Toni Stephenson, loving wife and mother who, after surviving lymphoma, passed away from pancreatic cancer in 2020.
'Pancreatic cancer remains one of the most challenging diseases to detect and treat, but we are making meaningful progress,' said Dr. Matthew Vander Heiden, the Lester Wolfe Chair in Molecular Biology and Professor of Biology at MIT. 'We're particularly encouraged by the potential to identify changes in normal pancreas function that could enable earlier detection—when treatment is most effective. The opportunity to rigorously test this idea is incredibly exciting, and I'm deeply grateful to the Stephenson Global Pancreatic Cancer Research Institute for supporting this ambitious work. Their investment in innovative research is helping move discoveries closer to the patients who need them most.'
A Collaborative Vision for a Global Challenge
The Stephenson Scholar Grants represent the largest source of private funding for pancreatic cancer research around the globe. Pancreatic cancer remains the deadliest cancer with a five-year survival rate of just 13% in the United States, impacting hundreds of thousands of families each year. The grants come at a time when federal funding for cancer research—already disproportionately low for pancreatic cancer—is facing an uncertain future.
These grants reflect the Institute's commitment to building a global, collaborative research ecosystem. This year's recipients span leading institutions in the U.S. and Canada, and their projects are designed to bridge disciplines, labs, and clinical settings. The winners were selected from a competitive pool of 188 applications spanning six continents, following a rigorous review by the Stephenson Scientific Advisory Board, comprising some of the world's foremost experts in pancreatic cancer.
The grants are part of a broader vision launched with a transformative $150 million gift from A. Emmet Stephenson Jr. and Tessa Stephenson Brand to accelerate discovery, foster partnership, and bring hope to patients and families worldwide. They selected City of Hope, a National Cancer Institute-designated comprehensive cancer center with a national footprint, to help facilitate the SGPCRI's various initiatives and bring together pancreatic cancer leaders in the search for new breakthroughs.
'Congratulations to the inaugural recipients of the Stephenson Global Scholar Grants,' said Daniel D. Von Hoff, M.D., chair of the Stephenson Scientific Advisory Board and distinguished professor at the Translational Genomics Research Institute, part of City of Hope. 'These awards support transformative approaches—from assessing pancreatic health and enabling earlier detection to advancing the latest immunotherapies. There has never been a more important time to unite around high-impact science. This teamwork between visionary philanthropists and some of the world's leading cancer institutions is bringing us closer to a future where pancreatic cancer is no longer a death sentence. We are also deeply grateful to the members of the Scientific Advisory Board for their wisdom and thoughtful deliberation in guiding this effort.'
For more information about the Stephenson Global Pancreatic Cancer Research Institute and the Stephenson Global Scholar Grants, visit sgpcri.global.
About the Stephenson Global Pancreatic Cancer Research Institute
The Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) is dedicated to transforming the future of pancreatic cancer research through groundbreaking innovation, global collaboration and strategic funding initiatives. Established through a transformative $150 million gift from philanthropists A. Emmet Stephenson Jr. and Tessa Stephenson Brand, SGPCRI is committed to advancing early detection, pioneering treatments and high-impact research to improve patient outcomes. Working with leading scientists, clinicians and institutions worldwide, SGPCRI fosters collaboration to accelerate breakthroughs in the fight against one of the world's most challenging cancers. For more information, visit us on our website or follow us on LinkedIn and X.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
Kerecis to Showcase Fish-Tissue Derived Tendon Protection Surgical Graft at APMA 2025
ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)--Kerecis, the company pioneering the use of fish-tissue in cellular therapy and tissue regeneration, will debut its latest innovation, SurgiBind® Tendon Protect, at the American Podiatric Medical Association's (APMA) Annual Scientific Meeting in Grapevine, Texas, July 24-27, 2025. The new biologic graft is designed for tendon procedures where no significant tissue loss is present and will be spotlighted during educational and interactive sessions throughout the conference. 'SurgiBind® Tendon Protect was developed in response to a need consistently identified by surgeons. Namely, coverage for repaired tendons that is straightforward to use and compatible with surgical workflows,' said Fertram Sigurjonsson, Founder and CEO of Share APMA 2025 As part of its presence at APMA 2025, Kerecis will exhibit at Booth #805 and host a clinical education event, 'Taste of Iceland,' on Friday, July 25, from 7:00 to 9:00 PM at Mission Plaza, Gaylord Texan Resort. During the session, Dr. James Cottom, DPM, will present 'Gliding into Enhanced Tendon Outcomes with Intact Fish Skin,' a talk exploring the clinical use of SurgiBind® Tendon Protect in tendon repair procedures. Attendees will also have the opportunity to learn more about the broader application of intact fish-tissue grafts while sampling traditional Icelandic cuisine. Designed for Tendon Protection and Surgical Efficiency Each year, an estimated 500,000 tendon procedures are performed in the United States, many of which aim to preserve or restore movement following tendon injury. SurgiBind® Tendon Protect is intended to be wrapped around a repaired tendon during surgery and is cleared for implantation to reinforce soft tissue where weakness exists. The product is a solid, intact fish-tissue based graft, sustainably sourced from North Atlantic cod, and is bioresorbable, non-crosslinked, and designed to be sutured and positioned with ease in the surgical field. 'Tendon Protect was developed in response to a need consistently identified by surgeons. Namely, coverage for repaired tendons that is straightforward to use and compatible with surgical workflows,' said Fertram Sigurjonsson, Founder and CEO of Kerecis. 'The result is a graft that is structurally sound and easy to handle, offering an alternative to mammalian-derived products.' Clinical Use SurgiBind® Tendon Protect is intended for use in ambulatory surgical centers (ASCs) and hospital outpatient departments (HOPDs), providing a physical covering around repaired tendons where there is no significant tissue loss. Its strength and pliability support secure placement and suture fixation and reduces the risk of readmissions or revision procedures related to scarring or adhesion, factors that can increase overall treatment costs and affect reimbursement. Audit-Ready™ To support providers, Kerecis offers coding and reimbursement guidance through its Audit-Ready™ program, designed to align with U.S. payor requirements, reduce administrative burden, and streamline claims and documentation. Available Nationwide SurgiBind® Tendon Protect marks the continued expansion of the Kerecis SurgiBind® portfolio, which now includes options for general surgical, trauma, and tendon-related procedures. The product is currently available across the United States through Kerecis' direct sales force. About Kerecis Kerecis, founded by Fertram Sigurjonsson, develops intact fish tissue derived products for cellular therapy, tissue regeneration, and protection. When grafted onto damaged human tissue or implanted, the patented material supports the body's own processes to heal and regenerate. Because no disease-transfer risk exists between cold-water fish and humans, Kerecis products are only gently processed and retain their similarity to human tissue. The gentle processing preserves the material's original three-dimensional structure, maintaining its inherent natural strength, complexity, and molecules (such as fatty acids). Clinical studies show that Kerecis products heal wounds faster than competitors. Kerecis is the only global manufacturer of medical devices containing intact fish-tissue and is the fastest growing company in the U.S. xenograft biologics skin market. Products include SurgiBind®/SurgiClose®, GraftGuide®, MariGen®, and Shield™ for various medical applications. Committed to the UN Sustainable Development Goals, Kerecis uses sustainably sourced Icelandic fish processed with renewable energy. Kerecis is a part of Coloplast, a leading supplier of intimate healthcare products. For more information about Kerecis and its clinical research, visit Trademarks and registered trademarks are the property of their respective owners.


Business Wire
3 hours ago
- Business Wire
A New Standard of Living: Vitacorps Begins Installation of Advanced Wellness Technology in U.S. Army Housing
WARWICK, R.I.--(BUSINESS WIRE)--Vitacorps, a leader in integrated wellness solutions for military environments, today announced the first installations of its innovative mission readiness solution are underway in homes at Fort Bragg, N.C., and Fort Meade, Md. This marks the beginning of a large-scale initiative to enhance the indoor environments of more than 4,500 homes across three major U.S. Army installations, including a future rollout at Fort Riley, Kan. The Vitacorps program is driven by a comprehensive process designed to help support the health, well-being, and readiness of service members and their families. This involves rigorous infield assessment of indoor conditions and resulting prescriptions of 3 rd -party tested interventions engineered to achieve certifiable indoor health outcomes across air and water quality, lighting and excess humidity. By holistically improving the indoor environment, Vitacorps aims to enhance soldier readiness, improve performance, strengthen family resilience, and contribute to the retention of military personnel. 'We are proud to begin the installation of our comprehensive wellness solution, bringing a new standard of healthy living to our nation's military families,' said Rob Bellmar, president of Vitacorps. 'Our seven-step program creates healthier living environments without major infrastructure investments or the need for temporary resident relocation. We bring together indoor environment and building experts to deliver scalable, research-based solutions that are designed to enhance well-being and operational effectiveness.' The initiative follows successful pilots that validated significant post-implementation enhancements to air and water quality, humidity control, and lighting conditions. Key enhancements being deployed include: Air Purification: Providing purified air throughout the entire home. Water Filtration: Ensuring access to high-quality filtered water. Excess Humidity Control: Implementing solutions to manage and reduce indoor humidity. Circadian Lighting: Installing lighting systems that support natural sleep cycles and increase mental acuity. Residents at a community participating in the pilot of the Vitacorps program reported an 82% increase in satisfaction with on-post housing. The U.S. Army approved the rapid rollout of the program to communities covering more than 15,000 residents after initial data showed an overwhelmingly positive response and significant improvements across multiple thresholds, with prototype installations being validated and certified to the WELL Building Standard™, the world's leading benchmark for indoor health. This initiative advances the National Defense Strategy's goal of a strong, healthy, and ready force and aligns with the Army's Holistic Health and Fitness (H2F) program, which promotes health and well-being for peak performance. About Vitacorps Vitacorps transforms military living with an evidence-based, integrated wellness solution designed to help enhance service members' health, performance, and quality of life. Unlike fragmented, one-off solutions, our comprehensive seven-step process improves indoor environmental quality to help bolster service member performance. Designed for scalability and streamlined implementation, the Vitacorps Program elevates military infrastructure into strategic assets that help bolster national defense and operational readiness.


Business Wire
3 hours ago
- Business Wire
Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care
SAN DIEGO--(BUSINESS WIRE)-- Vektor Medical today announced its vMap ® system has been used in more than 2,000 procedures in the U.S., a milestone that underscores its rapid adoption by electrophysiologists (EPs) and hospitals seeking to improve procedural efficiency, reduce repeat interventions, and deliver better patient outcomes. As adoption of PFA accelerates, the need for accurate, accessible data is greater than ever. vMap can enhance the impact of PFA by helping EPs identify optimal ablation targets before entering the lab and reiteratively during the procedure. vMap, developed with AI and designed to localize both focal and fibrillation-type arrhythmias, delivers actionable insights in all four chambers of the heart in less than a minute. Clinical studies have shown that use of vMap is associated with a reduction in procedure time, which may reduce fluoroscopy time and improve safety. vMap integrates seamlessly into existing systems, making it an increasingly valuable solution for electrophysiologists seeking greater efficiency and performance without compromise. vMap is now in use at over 20 hospitals throughout the United States. 'vMap has become an integral part of how I care for patients,' said Dr. Anish Amin, Section Chief, Electrophysiology, OhioHealth Heart and Vascular. 'It's efficient, non-invasive, and delivers insights that enhance every stage of the ablation process from planning through execution. With vMap, I can pinpoint arrhythmia sources faster with greater confidence, treat more accurately, and potentially reduce repeat interventions for patients. I'm looking forward to enrolling patients in the IMPRoVED-AF study, which will further validate the clinical impact of this technology and its potential to transform how we approach AF ablation.' As adoption of pulsed field ablation (PFA) accelerates, the need for accurate, accessible data is greater than ever. vMap can enhance the impact of PFA by helping EPs identify optimal ablation targets before entering the lab and reiteratively during the procedure. With vMap's rapid, non-invasive ECG-based driver localization, physicians have more information to better target areas of interest, supporting more efficient procedures and unlocking the full potential of PFA. 'This milestone represents meaningful momentum,' said Robert Krummen, CEO of Vektor Medical. 'With every procedure, physicians are leveraging vMap's rapid, non-invasive insights to make informed decisions and streamline care. We're seeing growing demand quarter over quarter as both physicians and hospitals look for ways to enhance efficiency and elevate patient care.' The vMap system is FDA-cleared and commercially available in the United States. As clinical use continues to expand, Vektor Medical remains focused on advancing the future of arrhythmia care through clinical innovation, strategic partnerships, and physician impact. To learn more about Vektor Medical, vMap technology, or to request a clinical or strategic briefing, visit and connect with us on LinkedIn and X. About Vektor Medical Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is improving outcomes, enhancing efficiencies, and accelerating access to effective treatment strategies. To learn more, visit